LIGAND PHARMACEUTICALS INCORPORATED Equity Securities, FV-NI
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Equity Securities, FV-NI of $35.20 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:EquitySecuritiesFvNi · last filed 2026-02-27
- 2025-12-31: Equity Securities, FV-NI $35.20M.
- 2025-06-30: Equity Securities, FV-NI $26.50M.
- 2024-12-31: Equity Securities, FV-NI $40.20M.
- 2023-12-31: Equity Securities, FV-NI $32.20M.
| Period end | Equity Securities, FV-NI | Equity Securities, FV-NI as first filed |
|---|---|---|
| 2025-12-31 | $35.20M 10-K · filed 2026-02-27 | |
| 2025-06-30 | $26.50M 10-Q · filed 2025-08-08 | |
| 2024-12-31 | $40.20M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $32.20M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $63.10M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $30.90M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $32.80M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $6.58M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $8.82M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $4.62M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $48.40M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $8.31M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $10.26M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $13.23M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $46.20M 10-K · filed 2020-02-27 | $46.19M 10-K · filed 2019-02-28 |
| 2018-09-30 | $105.18M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $59.80M 10-Q · filed 2018-08-08 | |
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 |